BioSpace News Archive

Insala, provider of the most comprehensive suite of cloud-based solutions supporting the employee career lifecycle, is proud to announce that it is launching a new ground-breaking platform to facilitate interaction and learning on the COVID-19 global pandemic, its short-term and long-term implications

The global biotechnology market is mainly driven by the surge in the demand for food, depleting natural resources, government regulatory support, and technological advancements of various solutions to counter fatal diseases.

The global diagnostic imaging market is expected to grow at a robust 6.0% CAGR during 2018-2026. Due to rise in chronic illnesses, the market is expected to reach $47 bn in the near future.

Transparency Market Research has published a new report titled ‘Mobility Aid Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global mobility aid devices market is projected to reach US$ 13,826.1 Mn by 2026, expanding at a single digit CAGR during the forecast period.

Transparency Market Research has published a new report titled, “Diagnostic Specialty Antibodies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Transparency Market Research has published a new report titled ‘Transfusion Technology Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026’.

Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that in connection with its previously completed underwritten offering on May 4, 2020 of $30,000,000 at a price of $6.25 per share, the option g

Recently presented promising XMT-1536 Phase 1 dose escalation data and established maximum tolerated dose, subsequently raising $65M of gross proceeds from the Company’s ATM facility Company to present interim data from the ongoing XMT-1536 Phase 1 dose expansion on a conference call on May 27, 2020 and at the upcoming American Society of Clinical Oncology (ASCO) 2020 virtual scientific program CAMBRIDGE, Mass., May 08, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a

140 patients with severe COVID-19 and ARDS to be treated Primary endpoint: ventilator free days during the main 28-day study period, secondary endpoint includes survival rate and ICU free days HAIFA, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Co

-Cash and investments of $114 million provide runway into 2022 - -Company will host virtual R&D event highlighting progress in its Synthetic Biotic platform and programs on Wednesday, May 27, 2020 - - Company will host a conference call at 8:00 am ET today -